Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award

PITTSBURGH, Sept. 22 /PRNewswire/ -- Precision Therapeutics announced today that President and Chief Executive Officer Sean McDonald received the Smart Business Magazine 2010 Pacesetters Award.  The award honors thirteen regional Pacesetters and recognizes the impact of their influence in the community-at-large as well as within their own organizations. The event took place on Tuesday, September 21st at the Kean Theatre in The Washington Place, Gibsonia, Pennsylvania.  Mr. McDonald was recognized as a leader in the mid-sized company category who is setting the pace for the Pittsburgh region.

(Photo: http://photos.prnewswire.com/prnh/20100922/NE69963 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100922/NE69963 )

"Being named a Smart Business Pacesetter is such an honor for me and my team as we work toward our goal of optimizing each patient's quality of life and chance for survival by designing advanced technology that offers hope for personalized cancer treatment," said McDonald.  "It is great to see that Pittsburgh is receiving recognition as a leader in the growing life science industry and a privilege to be a part of that development."

McDonald joined Precision Therapeutics in 2001 and serves as President and CEO. Previously, Mr. McDonald founded Automated Healthcare in 1992, developing the first robotics-based solution to hospital pharmacy management.  Mr. McDonald grew the company to over $150 million in revenues when it was acquired by the McKesson Corporation in 1996.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.  For more information, please visit www.precisiontherapeutics.com

About Pacesetters

The Pacesetter Awards are designed to recognize business leaders in the Greater Pittsburgh Area who are setting the pace for the region.  Leaders are recognized in three divisions based on the size of their organization, its revenue and overall story of success and influence within the organization as well as the community at large.

For more information, please visit www.sbnonline.com.

SOURCE Precision Therapeutics